Latest News about NVS
Recent news which mentions NVS
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
April 22, 2022
From Benzinga
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
April 21, 2022
From Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
From InvestorPlace
3 Fantastic Biotech Stocks to Buy in April
April 18, 2022
From Motley Fool
2 Unstoppable Green Flags for AbbVie
April 14, 2022
From Motley Fool
Biogen’s Aduhelm Crashes the Biotech Sector
April 13, 2022
From InvestorPlace
From Benzinga
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?
April 12, 2022
From Benzinga
Overview Of Value Stocks In The Healthcare Sector
April 11, 2022
From Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
From Benzinga
3 Things About Pfizer That Smart Investors Know
April 08, 2022
From Motley Fool
From InvestorPlace
From Benzinga
Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis
April 05, 2022
Tickers
NVS
From Benzinga
From Benzinga
7 Biotech Stocks to Buy With Key Catalysts for April
April 05, 2022
From InvestorPlace
From Benzinga
Novartis To Strengthen Pipeline, Boost Productivity With New Organizational Structure
April 04, 2022
Tickers
NVS
From Benzinga
3 CEOs to Invest In
April 01, 2022
From Motley Fool
From Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
March 28, 2022
From InvestorPlace
From Benzinga
From Motley Fool
Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD
March 25, 2022
Tickers
NVS
From Benzinga
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
March 24, 2022
From Motley Fool
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
March 24, 2022
From Benzinga
FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer
March 24, 2022
Tickers
NVS
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
More ways to get to us
Facebook
Twitter
YouTubeContact the Lethbridge Herald
504 - 7th Street South
Lethbridge, AB T1J 3Z7
[P] (403) 328-4411
[F] (403)328-4536
Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.